Comparison
Goserelin vs. Octreotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
65807-02-5
83150-76-9
Molecular weight
1269.43 g/mol
1019.24 g/mol
Half-life
4.2 h
1.7 h
Sequence
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Mechanism of action
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
4
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Goserelin and Octreotide?
- Goserelin is classified as "Research other", while Octreotide is classified as "Research other". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Octreotide?
- The highest available evidence level is "Human RCT" for Goserelin and "Human RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Octreotide in Germany and the United States?
- Germany: Goserelin — Prescription, Octreotide — Prescription. United States: Goserelin — Prescription, Octreotide — Prescription. These are factual summaries with source and review date on the individual pages.